Cellares, which last year became the first company to receive the FDA’s new advanced manufacturing technology designation, expects to support clinical production this year and offer commercial-scale manufacturing services in 2027.
BMS-Partnered Cellares Raises $257M for Cell Therapy Manufacturing Expansion